Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.phrs.2020.104859 http://scihub22266oqcxt.onion/10.1016/j.phrs.2020.104859 32360480!7189851!32360480     free     free     free       Pharmacol+Res 2020 ; 157 (ä): 104859 Nephropedia Template TP {{tp|p=32360480|t=2020. Candidate drugs against SARS-CoV-2 and COVID-19 |pdf=|usr=}}{{32360480}} gab.com Text Candidate drugs against SARS-CoV-2 and COVID-19 JO: Pharmacol Res http://www.kidney.de/pget.php?&tw=1&pmid=32360480 #FOAvip Outbreak and pandemic of coronavirus SARS-CoV-2 in 2019/2020 will challenge global health for the future. Because a vaccine against the virus will not be available in the near future, we herein try to offer a pharmacological strategy to combat the virus. There exists a number of candidate drugs that may inhibit infection with and replication of SARS-CoV-2. Such drugs comprise inhibitors of TMPRSS2 serine protease and inhibitors of angiotensin-converting enzyme 2 (ACE2). Blockade of ACE2, the host cell receptor for the S protein of SARS-CoV-2 and inhibition of TMPRSS2, which is required for S protein priming may prevent cell entry of SARS-CoV-2. Further, chloroquine and hydroxychloroquine, and off-label antiviral drugs, such as the nucleotide analogue remdesivir, HIV protease inhibitors lopinavir and ritonavir, broad-spectrum antiviral drugs arbidol and favipiravir as well as antiviral phytochemicals available to date may limit spread of SARS-CoV-2 and morbidity and mortality of COVID-19 pandemic. Twit Text FOAVip Candidate drugs against SARS-CoV-2 and COVID-19 ????Pharmacol Res http://www.kidney.de/pget.php?&tw=1&pmid=32360480 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32360480 #FOAvip English Wikipedia <ref>{{Cite pmid|32360480}}</ref> Candidate drugs against SARS-CoV-2 and COVID-19 #MMPMID32360480 McKee DL; Sternberg A; Stange U; Laufer S; Naujokat C Pharmacol Res 2020[Jul]; 157 (ä): 104859 PMID32360480show ga Outbreak and pandemic of coronavirus SARS-CoV-2 in 2019/2020 will challenge global health for the future. Because a vaccine against the virus will not be available in the near future, we herein try to offer a pharmacological strategy to combat the virus. There exists a number of candidate drugs that may inhibit infection with and replication of SARS-CoV-2. Such drugs comprise inhibitors of TMPRSS2 serine protease and inhibitors of angiotensin-converting enzyme 2 (ACE2). Blockade of ACE2, the host cell receptor for the S protein of SARS-CoV-2 and inhibition of TMPRSS2, which is required for S protein priming may prevent cell entry of SARS-CoV-2. Further, chloroquine and hydroxychloroquine, and off-label antiviral drugs, such as the nucleotide analogue remdesivir, HIV protease inhibitors lopinavir and ritonavir, broad-spectrum antiviral drugs arbidol and favipiravir as well as antiviral phytochemicals available to date may limit spread of SARS-CoV-2 and morbidity and mortality of COVID-19 pandemic. |Angiotensin-Converting Enzyme 2[MESH] |Angiotensin-Converting Enzyme Inhibitors/pharmacology[MESH] |Antiviral Agents/pharmacology/therapeutic use[MESH] |Betacoronavirus/*drug effects[MESH] |COVID-19[MESH] |Coronavirus Infections/*drug therapy/epidemiology/mortality[MESH] |Humans[MESH] |Pandemics[MESH] |Peptidyl-Dipeptidase A/*drug effects[MESH] |Pneumonia, Viral/*drug therapy/epidemiology/mortality[MESH] |SARS-CoV-2[MESH] |Serine Endopeptidases/*drug effects[MESH]Candidate drugs against SARS-CoV-2 and COVID-19 (epmc).pdf DeepDyve Pubget Overpricing